Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Safety and Efficacy Study of Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT07601295 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07601295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07601295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Safety and Efficacy Study of Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
March 31, 2030
Enrollment
90 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)